Editors’ Picks: Highlights from AACR Journals
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer screening method.
Progress Against Cancer
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer screening method.
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
SABCS panel describes advances and pivotal questions in managing patients whose breast cancer has metastasized to their brain.
“What will you do Monday morning?” was the question posed by the final session on the final full day of the 2023 San Antonio Breast Cancer Symposium (SABCS), held Tuesday, December 5 to Saturday,...
Progression-free survival among certain patients with metastatic colorectal cancer continued at a high level after immune checkpoint inhibitor therapy was stopped. Some patients with metastatic colorectal cancer who benefit from immunotherapy are reluctant to...
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for the treatment of patients with locally advanced or...
Study finds breast cancer survivors can opt for less frequent screening, and people with physical disabilities often encounter discrimination in cancer care.
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and color of one of her breasts, accompanied by new shooting pains. The radiologist who reviewed...
Belzutifan is now available for certain patients with kidney cancer whether or not they have von Hippel-Lindau disease. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now